Announcements Trials

Browse Landscape

Phase

Phase 3 5 Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lambert-Eaton Myasthenic Syndrome 1

Interventions

Cisplatin 1514 Carboplatin 1416 Cyclophosphamide 1359 Gemcitabine 1235 Bevacizumab 1223 Paclitaxel 1210 Radiotherapy 1173 Docetaxel 1079 pembrolizumab 1026 Oxaliplatin 934 Capecitabine 898 Fluorouracil 832 Rituximab 729 Doxorubicin 683 Nivolumab 679 Dexamethasone 665 Etoposide 660 Irinotecan 622 Leucovorin 574 Pemetrexed 508 Drug Therapy 491 Cetuximab 481 Trastuzumab 467 Cytarabine 466 Magnetic Resonance Spectroscopy 457 Filgrastim 446 Prednisone 432 Lenalidomide 409 Specimen Handling 407 Temozolomide 400

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Amifampridine × Clear all

NCT01511978 2017-07-11

DAPPER

Jacobus Pharmaceutical

Phase 2 Completed

32 enrolled 16 charts

Lambert-Eaton Myasthenic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡